骨质疏松症的最新影像学进展
骨质疏松症在老年人群中常见,DXA 是诊断和评估的金标准。本文综述机会性 CT、定量 CT、先进 MRI 技术(QSM、磁共振波谱、CSE-MRI)、定量超声及 NaF-PET/CT 等放射性示踪剂混合方法在评估骨质量、骨转换和骨折风险中的研究进展,其中骨质疏松患者 NaF 摄取减低。
要点
- DXA 测量骨密度(BMD)并按标准差计算评分,目前仍是诊断和评估骨质疏松进展与治疗的金标准。
- 机会性 CT 与定量 CT 可用于判断骨折风险并进行比 DXA 更细致的骨质量分析。
- NaF-PET/CT 等混合方法中骨质疏松患者放射性示踪剂摄取减低,可能比传统生物标志物更早检出骨质疏松。
核心结论
- 分子影像在骨质疏松预测及替代侵入性诊断操作方面显示出特别的前景。
- 放射性示踪剂可能为临床医生提供比传统生物标志物更早的骨质疏松检出窗口。
研究设计与样本
- 本文为综述,回顾历史及当前关于可提供更细致或机会性骨质量、骨转换和骨密度分析的新影像模态的研究。
主要发现
- DXA 通过测量骨密度并依据测得骨密度与均值之差的标准差计算评分。
- 机会性 CT 和定量 CT 有助于判断骨折风险并进行比 DXA 更详细的骨质量分析。
- 先进 MRI 技术包括定量磁敏感图(QSM)、磁共振波谱和基于化学位移编码的水脂 MRI(CSE-MRI),可改善对非矿化骨间室的评估,并可在不反复接受电离辐射的情况下纵向评估骨质量。
- 定量超声的发展在未來低成本、广泛可及的筛查工具方面显示出前景。
- 在 NaF-PET/CT 等混合方法中,骨质疏松患者对 NaF 等放射性示踪剂的摄取减低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis is a common disease, particularly prevalent in geriatric populations, which causes significant worldwide morbidity due to increased bone fragility and fracture risk. Currently, the gold-standard modality for diagnosis and evaluation of osteoporosis progression and treatment relies on dual-energy x-ray absorptiometry (DXA), which measures bone mineral density (BMD) and calculates a score based upon standard deviation of measured BMD from the mean. However, other imaging modalities can also be used to evaluate osteoporosis. Here, we review historical as well as current research into development of new imaging modalities that can provide more nuanced or opportunistic analyses of bone quality, turnover, and density that can be helpful in triaging severity and determining treatment success in osteoporosis. We discuss the use of opportunistic computed tomography (CT) scans, as well as the use of quantitative CT to help determine fracture risk and perform more detailed bone quality analysis than would be allowed by DXA . Within magnetic resonance imaging (MRI), new developments include the use of advanced MRI techniques such as quantitative susceptibility mapping (QSM), magnetic resonance spectroscopy, and chemical shift encoding-based water-fat MRI (CSE-MRI) to enable clinicians improved assessment of nonmineralized bone compartments as well as a way to longitudinally assess bone quality without the repeated exposure to ionizing radiation. Within ultrasound, development of quantitative ultrasound shows promise particularly in future low-cost, broadly available screening tools. We focus primarily on historical and recent developments within radiotracer use as applicable to osteoporosis, particularly in the use of hybrid methods such as NaF-PET/CT, wherein patients with osteoporosis show reduced uptake of radiotracers such as NaF. Use of radiotracers may provide clinicians with even earlier detection windows for osteoporosis than would traditional biomarkers. Given the metabolic nature of this disease, current investigation into the role molecular imaging can play in the prediction of this disease as well as in replacing invasive diagnostic procedures shows particular promise.
引用
- Chen M, Gerges M, Raynor WY, et al. State of the Art Imaging of Osteoporosis. Semin Nucl Med. 2023. PMID: 38087745. doi:10.1053/j.semnuclmed.2023.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。